ImmunityBio's Anktiva Receives FDA Approval for Expanded Indication

12:06 PM EDT, 10/14/2026 (MT Newswires) -- ImmunityBio's (IBRX) Anktiva was approved by the Food and Drug Administration for adults with Bacillus Calmette-Guerin-unresponsive non-muscle invasive bladder cancer, the FDA said Wednesday The approval expands the previous indication for adults with bladder cancer with carcinoma in situ, with or without papillary tumors, to include those with high-grade papillary-only tumors, according to a statement. Trial efficacy data for patients with bladder cancer with carcinoma in situ previously showed that 58% with a complete response had a duration of response of at least 12 months, according to the FDA. Price: 9.75, Change: -0.05, Percent Change: -0.51